Literature DB >> 26547309

Comment on Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.

Joseph F Standing1, Brian J Anderson2, Nicholas H G Holford3, Irja Lutsar4, Tuuli Metsvaht5.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26547309     DOI： 10.1007/s40262-015-0344-5

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  6 in total

1.  Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies.

Authors:  Yaning Wang; Pravin R Jadhav; Mallika Lala; Jogarao V Gobburu
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.

Authors:  Wei Zhao; Helen Hill; Chantal Le Guellec; Tim Neal; Sarah Mahoney; Stephane Paulus; Charlotte Castellan; Behrouz Kassai; Johannes N van den Anker; Gregory L Kearns; Mark A Turner; Evelyne Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.

Authors:  Stéphanie Leroux; Mark A Turner; Chantal Barin-Le Guellec; Helen Hill; Johannes N van den Anker; Gregory L Kearns; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

4.  Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children.

Authors:  F Mentré; C Dubruc; J P Thénot
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

5.  Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.

Authors:  Vanessa E Rees; Jürgen B Bulitta; Roger L Nation; Brian T Tsuji; Fritz Sörgel; Cornelia B Landersdorfer
Journal:  J Antimicrob Chemother       Date:  2014-11-06       Impact factor: 5.790

6.  Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial.

Authors:  Irja Lutsar; Ursula M T Trafojer; Paul T Heath; Tuuli Metsvaht; Joseph Standing; Susanna Esposito; Vincent Meiffredy de Cabre; Clarissa Oeser; Jean-Pierre Aboulker
Journal:  Trials       Date:  2011-09-30       Impact factor: 2.279
  6 in total
  5 in total

1.  Author's Reply to Standing et al. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.

Authors:  Wei Zhao; Evelyne Jacqz-Aigrain
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

2.  Development of a Novel Multipenicillin Assay and Assessment of the Impact of Analyte Degradation: Lessons for Scavenged Sampling in Antimicrobial Pharmacokinetic Study Design.

Authors:  Karin Kipper; Charlotte I S Barker; Joseph F Standing; Mike Sharland; Atholl Johnston
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Dosing of Ceftriaxone and Metronidazole for Children With Severe Acute Malnutrition.

Authors:  Joseph F Standing; Martin O Ongas; Caroline Ogwang; Nancy Kagwanja; Sheila Murunga; Shalton Mwaringa; Rehema Ali; Neema Mturi; Moline Timbwa; Christine Manyasi; Laura Mwalekwa; Victor L Bandika; Bernhards Ogutu; Joseph Waichungo; Karin Kipper; James A Berkley
Journal:  Clin Pharmacol Ther       Date:  2018-04-19       Impact factor: 6.875

Review 4.  Pharmacokinetic studies in children: recommendations for practice and research.

Authors:  Charlotte I S Barker; Joseph F Standing; Lauren E Kelly; Lauren Hanly Faught; Allison C Needham; Michael J Rieder; Saskia N de Wildt; Martin Offringa
Journal:  Arch Dis Child       Date:  2018-04-19       Impact factor: 3.791

Review 5.  Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.

Authors:  Eva Germovsek; Charlotte I S Barker; Mike Sharland; Joseph F Standing
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 5.577
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.